Litcius/Paper detail

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

Shankar Siva, Mathias Bressel, Mark Sidhom, Swetha Sridharan, Ben Vanneste, Ryan Davey, Rebecca Montgomery, Jeremy Ruben, Farshad Foroudi, Braden Higgs, Charles Lin, Avi Raman, Nicholas Hardcastle, Michael S. Hofman, Richard De Abreu Lourenço, Mark Shaw, Pascal Mancuso, Daniel Moon, Lih‐Ming Wong, Nathan Lawrentschuk, Simon Wood, Nicholas R. Brook, Tomas Kron, Jarad Martin, David Pryor, Brent Chesson, Muhammad Ali, Sarat Chander, Alisha Moore, Olivia Cook, Thomas Eade, Harish Sharma, Muralidas Ramanathan, Kate Howe, Helen Frewen

2024The Lancet Oncology105 citationsDOI

Topics & Concepts

SABR volatility modelAblative caseMedicineRadiation therapyCancerKidney cancerClinical trialSurgeryInternal medicineVolatility (finance)EconomicsFinancial economicsStochastic volatilityRenal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsKidney Stones and Urolithiasis Treatments